ABIRATERONE EXPANDED ACCESS Trial Site Contact Info – 3/25/11 for men with advanced prostate cancer (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic prostate cancer 3. no brain metastasis 4. failed chemo 5. no more than 2 different types of previous chemo […]
Bristol-Myers Squibb Co. announced today (March 25) that it has received FDA approval for ipilimumab, the first drug in a new family of medicines to treat advanced melanoma, the most deadly form of skin cancer. This is potentially good news for those of us who are fighting advanced prostate cancer as there is currently an [...]
Increasingly it has become obvious to me and to many other individuals that our current drug approval and development process has a basic flaw. If you go to research conferences you quickly learn that there is probably no magic bullet to stop any type of cancer, including advanced prostate cancer. Current drug development focuses on [...]
Firmagon, the newly FDA approved gonadotropin-releasing hormone (GnRH) receptor blocker should perhaps be considered as a better alternative to the traditionally used ADT drugs like lupron and zoladex (GnRH agonists) which are the current standard of care. Recent data released from the ongoing five-year Firmagon (degarelix) extension study (CS21a) has demonstrated the long term efficacy [...]
Bisphosphonates, specifically Zometa, is commonly used in the treatment of men with advanced prostate cancer. Zometa is used to treat and protect bones from developing fractures. Bisphosphonates are potent inhibitors of bone resorption. Additionally, in vitro studies show that zolendronic acid also inhibits prostate cancer cell growth by activating apoptosis (A form of cell death [...]
As we all anxiously wait for the FDA to finally make a determination about the pending application for approval of the investigational androgen biosynthesis inhibitor abiraterone acetate more data rolls in showing that supports the need to have a speedy approval. A new study published March 1, 2011, out of Italy adds support to the [...]
A new Phase 2 clinical trial of tesetaxel in men with castrate resistant advanced prostate cancer will be conducted through the Prostate Cancer Clinical Trials Consortium (PCCTC). Tesetaxel, an oral taxane which is in clinical development, will be evaluated for its use as both first- and second-line chemotherapy. […]
The Washington Post has written an article about the funding controversy surrounding the Department of Defense (DOD) Medical Research Programs. I urge everyone to go to the web site and add your comments. Members of congress do read the Washington Post daily. Please go to: The Washington Post It would be a good idea if [...]
Researchers at the Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy performed a randomized phase II study which compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the standard of care D/prednisone (P) in men with advanced castrate-resistant prostate cancer (CRPC). […]
Tomorrow, Wednesday- March 2, I will be joining Dr. Daniel Petrylak for a number of radio interviews about prostate cancer. Dr. Petrylak is a world renowned prostate cancer researcher and clinician. He was the principal investigator in for the development of Taxotere (docetaxel). I anticipate that we will cover a number of different prostate cancer [...]
